Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of Rifaximin on Liver Fibrosis in HIV-Infected Patients With Liver Disease

NCT01654939 is registered in ClinicalTrials.gov with Douglas T. Dieterich as lead sponsor.

NCT NCT01654939
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01654939 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of Rifaximin on Liver Fibrosis in HIV-Infected Patients With Liver Disease
Lead sponsor
Douglas T. Dieterich
Phase
Phase 4
Overall status
Withdrawn
Start date
October 31, 2012
Completion date
September 30, 2015
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c, hiv